Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer

Surgical Oncology

Volumn 18, Issue 1, 2009, Pages 15-24

  Tan, Emile ^a   Gouvas, Nikos ^a,b   Nicholls, R John ^a   Ziprin, Paul ^a   Xynos, Evaghelos ^b   Tekkis, Paris P ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cancer; Carcinoembryonic antigen; CEA; Colorectal; Diagnosis; Recurrence

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY;

EID: 60549088708     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2008.05.008     Document Type: Review

References (57)

1. Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 38 7 (2002) 986-999
2. Flamini E., Mercatali L., Nanni O., Calistri D., Nunziatini R., Zoli W., et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12 23 (2006) 6985-6988
3. Gold P., and Freedman S.O. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122 3 (1965) 467-481
4. van der Schouw Y.T., Verbeek A.L., Wobbes T., Segers M.F., and Thomas C.M. Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma. Br J Cancer 66 1 (1992) 148-154
5. George P.K., Loewenstein M.S., O'Brien M.J., Bronstein B., Koff R.S., and Zamcheck N. Circulating CEA levels in patients with fulminant hepatitis. Dig Dis Sci 27 2 (1982) 139-142
6. Rockall T.A., and McDonald P.J. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis 14 1 (1999) 73-77
7. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., and Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270 8 (1993) 943-947
8. Wang J.Y., Tang R., and Chiang J.M. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 37 3 (1994) 272-277
9. Kievit J., and van de Velde C.J. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 65 11 (1990) 2580-2587
10. Vignati P.V., and Roberts P.L. Preoperative evaluation and postoperative surveillance for patients with colorectal carcinoma. Surg Clin North Am 73 1 (1993) 67-84
11. Hida J., Yasutomi M., Shindoh K., Kitaoka M., Fujimoto K., Ieda S., et al. Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum 39 1 (1996) 74-79
12. Kelly C.J., and Daly J.M. Colorectal cancer. Principles of postoperative follow-up. Cancer 70 Suppl. 5 (1992) 1397-1408
13. Barillari P., Sammartino P., Cardi M., Ricci M., Gozzo P., Cesareo S., et al. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences. Aust N Z J Surg 61 9 (1991) 675-680
14. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326 7379 (2003) 41-44
15. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., and Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3 (2003) 25
16. Littenberg B., and Moses L.E. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making 13 4 (1993) 313-321
17. Moses L.E., Shapiro D., and Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12 14 (1993) 1293-1316
18. Walter S.D. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21 9 (2002) 1237-1256
19. Irwig L., Tosteson A.N., Gatsonis C., Lau J., Colditz G., Chalmers T.C., et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 120 8 (1994) 667-676
20. Jaeschke R., Guyatt G., and Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-based medicine working group. JAMA 271 5 (1994) 389-391
21. Jaeschke R., Guyatt G.H., and Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The evidence-based medicine working group. JAMA 271 9 (1994) 703-707
22. Lucha Jr. P.A., Rosen L., Olenwine J.A., Reed III J.F., Riether R.D., Stasik Jr. J.J., et al. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum 40 2 (1997) 145-149
23. Seregni E., Bombardieri E., Bogni A., Crippa F., De Jager E., and Buraggi G.L. The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan. Int J Biol Markers 7 3 (1992) 167-170
24. Begg C.B., and McNeil B.J. Assessment of radiologic tests: control of bias and other design considerations. Radiology 167 2 (1988) 565-569
25. Vyslouzil K., Klementa I., Stary L., Duda M., Skalicky P., Kapustova M., et al. Oncologic markers in patients with colorectal cancer after a complex therapy. Bratisl Lek Listy 105 10-11 (2004) 389-391
26. Hall N.R., Finan P.J., Stephenson B.M., Purves D.A., and Cooper E.H. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. Br J Cancer 70 3 (1994) 549-553
27. Meling G.I., Rognum T.O., Clausen O.P., Bormer O., Lunde O.C., Schlichting E., et al. Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients. Scand J Gastroenterol 27 12 (1992) 1061-1068
28. Staib L., Link K.H., and Beger H.G. Follow-up in colorectal cancer: cost-effectiveness analysis of established and novel concepts. Langenbecks Arch Surg 385 6 (2000) 412-420
29. Korner H., Soreide K., Stokkeland P.J., and Soreide J.A. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Ann Surg Oncol (2006)
30. Bronstein B.R., Steele Jr. G.D., Ensminger W., Kaplan W.D., Lowenstein M.S., Wilson R.E., et al. The use and limitations of serial plasma carcinoembryonic antigen (CEA) levels as a monitor of changing metastatic liver tumor volume in patients receiving chemotherapy. Cancer 46 2 (1980) 266-272
31. Park Y.A., Lee K.Y., Kim N.K., Baik S.H., Sohn S.K., and Cho C.W. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol 13 5 (2006) 645-650
32. Arnaud J.P., Koehl C., and Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 23 3 (1980) 141-144
33. Bleeker W.A., Mulder N.H., Hermans J., Otter R., and Plukker J.T. Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer. Br J Surg 88 1 (2001) 101-106
34. Martin Jr. E.W., Cooperman M., Carey L.C., and Minton J.P. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res 28 5 (1980) 389-394
35. Goslin R., O'Brien M.J., Steele G., Mayer R., Wilson R., Corson J.M., et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med 71 2 (1981) 246-253
36. Moertel C.G., O'Fallon J.R., Go V.L., O'Connell M.J., and Thynne G.S. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 58 3 (1986) 603-610
37. Chau I., Allen M.J., Cunningham D., Norman A.R., Brown G., Ford H.E., et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 22 8 (2004) 1420-1429
38. Arnaud J.P., Cervi C., Bergamaschi R., and Tuech J.J. Value of oncologic follow-up of patients operated for colorectal cancer. A prospective study of 1000 patients. J Chir (Paris) 134 2 (1997) 45-50
39. Rocklin M.S., Slomski C.A., and Watne A.L. Postoperative surveillance of patients with carcinoma of the colon and rectum. Am Surg 56 1 (1990) 22-27
40. Carpelan-Holmstrom M., Louhimo J., Stenman U.H., Alfthan H., Jarvinen H., and Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol 25 5-6 (2004) 228-234
41. Griesenberg D., Nurnberg R., Bahlo M., and Klapdor R. Cea, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 19 4A (1999) 2443-2450
42. Holubec Jr. L., Topolcan O., Pikner R., Pecen L., Vaclavickova J., Wirthova M., et al. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. Anticancer Res 20 6D (2000) 5237-5244
43. Nicolini A., Caciagli M., Zampieri F., Ciampalini G., Carpi A., Spisni R., et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Detect Prev 19 2 (1995) 183-195
44. Fernandes L.C., Kim S.B., Saad S.S., and Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol 12 24 (2006) 3891-3894
45. Miki C., Inoue Y., Hiro J., Ojima E., Araki T., Uchida K., et al. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Dis Colon Rectum 49 11 (2006) 1710-1718
46. Behbehani A.I., al-Naqeeb N., Omar Y.T., el-Nas S.A., al-Deen A.S., Awwad A., et al. Serial determinations of serum CEA in monitoring management of patients with colorectal carcinoma. Oncology 47 4 (1990) 303-307
47. Li Destri G., Greco S., Rinzivillo C., Racalbuto A., Curreri R., and Di Cataldo A. Monitoring carcinoembryonic antigen in colorectal cancer: is it still useful?. Surg Today 28 12 (1998) 1233-1236
48. McCall J.L., Black R.B., Rich C.A., Harvey J.R., Baker R.A., Watts J.M., et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 37 9 (1994) 875-881
49. Novell F., Trias M., Molina R., and Filella X. Detection of occult liver metastases in colorectal cancer by measurement of biliary carcinoembryonic antigen. Anticancer Res 17 4A (1997) 2743-2746
50. Staib L., Schirrmeister H., Reske S.N., and Beger H.G. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. Am J Surg 180 1 (2000) 1-5
51. Barillari P., Ricci M., Broglia S., Manetti G., Cerasi A., Cesareo S., et al. Effectiveness of quarterly assessment of CEA, TPA and GICA serum levels in gastric and colorectal carcinomas: prospective study of 174 patients undergoing radical surgery. Minerva Chir 49 10 (1994) 953-961
52. Engaras B., Kewenter J., Nilsson O., Wedel H., and Hafstrom L. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. Eur J Surg Oncol 27 1 (2001) 43-48
53. Ishikawa H., Fujii H., Yamamoto K., Morita T., Hata M., Koyama F., et al. Tumor angiogenesis predicts recurrence with normal serum carcinoembryonic antigen in advanced rectal carcinoma patients. Surg Today 29 10 (1999) 983-991
54. Tobaruela E., Enriquez J.M., Diez M., Camunas J., Muguerza J., and Granell J. Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level. Int J Biol Markers 12 1 (1997) 18-21
55. Filella X., Molina R., Pique J.M., Garcia-Valdecasas J.C., Grau J.J., Novell F., et al. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biol 15 1 (1994) 1-6
56. Hung G.U., Shiau Y.C., Tsai S.C., Chao T.H., Ho Y.J., and Kao C.H. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 21 2B (2001) 1375-1378
57. Spila A., Ferroni P., Cosimelli M., D'Alessandro R., Abbolito M.R., Mariotti S., et al. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation. Anticancer Res 21 2B (2001) 1263-1270